| scholarly article | Q13442814 |
| P2093 | author name string | Gregory J Kaczorowski | |
| Maria L Garcia | |||
| Stephen D Hess | |||
| Umesh A Patel | |||
| Jacob Bode | |||
| P2860 | cites work | Identifying R&D outliers | Q84859599 |
| Inwardly rectifying potassium channels: their structure, function, and physiological roles | Q24296441 | ||
| Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site | Q27638349 | ||
| Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes | Q30466591 | ||
| Drug-induced prolongation of the QT interval | Q33151147 | ||
| Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities | Q33603023 | ||
| Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker | Q34113486 | ||
| The impact of drug-induced QT interval prolongation on drug discovery and development | Q34201433 | ||
| Cardiac ion channels | Q34516208 | ||
| Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development | Q35095735 | ||
| Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. | Q35264421 | ||
| QPatch: the past, present and future of automated patch clamp | Q36425985 | ||
| Can pharmacogenetics help rescue drugs withdrawn from the market? | Q36596713 | ||
| Innovative approaches to anti-arrhythmic drug therapy. | Q36670460 | ||
| Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines | Q36736498 | ||
| Extracellular loop C of NPC1L1 is important for binding to ezetimibe | Q36837498 | ||
| A genetic framework for improving arrhythmia therapy. | Q37089729 | ||
| Use of planar array electrophysiology for the development of robust ion channel cell lines | Q37370185 | ||
| KCNH2 pharmacogenomics summary | Q37691207 | ||
| Electrophysiologic, pharmacokinetic, and pharmacodynamic values indicating a higher risk of torsades de pointes | Q37765087 | ||
| ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. | Q38288024 | ||
| A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors. | Q39319984 | ||
| Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators | Q39685528 | ||
| Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels | Q39707961 | ||
| The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes | Q39739924 | ||
| Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes | Q39759039 | ||
| Automated patch-clamp technique: increased throughput in functional characterization and in pharmacological screening of small-conductance Ca2+ release-activated Ca2+ channels | Q39965395 | ||
| Madin-Darby canine kidney II cells: a pharmacologically validated system for NPC1L1-mediated cholesterol uptake | Q40026522 | ||
| Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. | Q40047575 | ||
| Functional assay of voltage-gated sodium channels using membrane potential-sensitive dyes. | Q40529990 | ||
| Molecular cloning, distribution and functional analysis of the NA(V)1.6. Voltage-gated sodium channel from human brain | Q40719915 | ||
| Lidocaine block of cardiac sodium channels | Q41556598 | ||
| Ion channels as drug targets: the next GPCRs | Q42038331 | ||
| A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. | Q42726669 | ||
| To the editor--Market withdrawal of quinidine bisulfate (Kinidin Durules) in 2006. | Q43131352 | ||
| Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. | Q46436523 | ||
| A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel. | Q51770370 | ||
| P304 | page(s) | 78 | |
| P577 | publication date | 2011-12-13 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling | |
| P478 | volume | 2 |
| Q44588171 | Automated Patch Clamp Analysis of nAChα7 and Na(V)1.7 Channels |
| Q28533477 | Bioactivity of fungal endophytes as a function of endophyte taxonomy and the taxonomy and distribution of their host plants |
| Q28598207 | Evaluation of bioactive secondary metabolites from endophytic fungus Pestalotiopsis neglecta BAB-5510 isolated from leaves of Cupressus torulosa D.Don |
| Q35937895 | Ion channel screening: advances in technologies and analysis |
| Q34655968 | Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file |
Search more.